- Report
- January 2023
- 282 Pages
Global
From €3221EUR$3,600USD£2,832GBP
- Report
- January 2023
- 109 Pages
Europe
From €1342EUR$1,500USD£1,180GBP
- Report
- January 2023
- 109 Pages
Africa, Middle East
From €1342EUR$1,500USD£1,180GBP
- Report
- January 2023
- 109 Pages
Asia Pacific
From €1342EUR$1,500USD£1,180GBP
- Report
- January 2023
- 96 Pages
North America
From €1342EUR$1,500USD£1,180GBP
- Map
- November 2022
Europe
- Map
- October 2022
Global
- Report
- May 2025
- 148 Pages
India
From €2237EUR$2,500USD£1,966GBP
- Report
- April 2025
- 142 Pages
Italy
From €2237EUR$2,500USD£1,966GBP
- Report
- July 2023
- 115 Pages
Global
From €4026EUR$4,500USD£3,539GBP
- Report
- January 2022
- 243 Pages
Europe
From €4965EUR$5,550USD£4,365GBP
- Report
- January 2024
- 109 Pages
Global
From €3500EUR$4,191USD£3,185GBP
- Report
- July 2024
- 132 Pages
Global
From €850EUR$950USD£747GBP
- Report
- January 2024
Global
From €3131EUR$3,500USD£2,753GBP

The Contract Development and Manufacturing Organization (CDMO) market is a subset of the pharmaceutical manufacturing industry. It is composed of companies that provide services to pharmaceutical and biotechnology companies, such as drug development, clinical trial materials, and commercial manufacturing. CDMOs are typically engaged by pharmaceutical companies to outsource the development and manufacturing of their products. This allows the pharmaceutical companies to focus on their core competencies, such as drug discovery and marketing.
CDMOs provide a range of services, including process development, analytical services, formulation development, clinical trial materials, and commercial manufacturing. They also provide regulatory support, such as filing of Investigational New Drug (IND) applications and New Drug Applications (NDAs).
Some of the major players in the CDMO market include Lonza, Patheon, Boehringer Ingelheim, Catalent, and Ajinomoto. Other companies in the market include Recipharm, Jubilant, Vetter, and Fareva. Show Less Read more